Daniel Bohl, MD
Orthopaedic Surgery · Dallas, TXNPI 1336521582
Payments from drug & device makers
What this record shows
This record is dominated by grants: $10,000 of the $16,013 with a category attached, or 62.4%. Arthrex accounts for 62.4% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2020 at $10,218 and has fallen 90.0% since, to $1,022 in 2025.
Across 70 payments — averaging $228.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$10K
- Stryker$5K
- Lightbody Medical Technologies Inc$405
- Medwest Associates$357
- Fusion Orthopedics USA, LLC$343
- Paragon 28, Inc.$138
- plus $214 from 6 others
What the payments were for
- Grants$10,00062%
- Food & beverage$5,40634%
- Education$6074%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 1 | $10,000 |
| Stryker(2 entities) | 54 | $4,556 |
| Lightbody Medical Technologies Inc | 3 | $405 |
| Medwest Associates | 3 | $357 |
| Fusion Orthopedics USA, LLC | 1 | $343 |
| Paragon 28, Inc. | 1 | $138 |
| Zimmer Biomet | 2 | $80 |
| Acumed LLC | 1 | $41 |
| Pacira Pharmaceuticals Incorporated | 1 | $37 |
| Davol Inc. | 1 | $21 |
| Orthofix Medical, Inc. | 1 | $19 |
| Smith+Nephew | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INFINITY$2,051
- TRAUMA$266
- AUGMENT INJECTABLE$221
- PROSTEP MICA$166
- T2$162
- AXSOS$150
- Portfolio$138
- ALLOMATRIX$134
- Actishield$109
How this compares
$16,013 in reported general payments places this provider in the 75th percentile of 1,337 orthopaedic surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 50 | $2,587 |
| Meloxicam | 201 | $570 |
| Cefadroxil | 11 | $113 |
| Clindamycin Hcl | 11 | $80 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Dallas
- Richard JonesDallas$6.3M
- James BrodskyDallas$2.5M
- Sumant KrishnanDallas$1.9M
- Wayne BurkheadDallas$1.2M
- Bradford WaddellDallas$325K
- Jay MabreyDallas$310K
- Eddie LoDallas$276K
- Clinton BellDallas$261K
- Jesus ReyDallas$227K
- Stephen BurkhartSan Antonio$185.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.